Blood transfusion is the most common form of transplantation in current practice. Worldwide, 75 million units of blood are donated every year. Of these, 24 million units are transfused in the United States reflecting a high economic and health care burden. [1] [2] [3] In cardiac surgery, 50% of patients receive transfusions, and up to a fifth of these patients utilize the majority of blood products intraoperatively. 2 This translates to 20% of the available U.S. supply.
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Notwithstanding its well-known complications, there is increasing evidence suggesting that blood transfusion is associated with an increase in morbidity and mortality, in both the short and long term. However, the evidence is conflicting, and transfusion policies in cardiac surgery vary widely. This absence of consensus is even greater in aortic surgery, where research does not adequately address the issue of outcomes. [4] [5] [6] Transfusion policies are often extrapolated from studies examining other cardiac procedures (e.g., coronary artery bypass grafting [CABG] , valve replacement). Here, we briefly summarize the benefits and risks of blood transfusion before reviewing current practices in cardiac surgery. We focus on the effects of perioperative transfusion on outcomes, with an emphasis on the management of patients undergoing aortic procedures.
Benefits and Risks of Blood Transfusion
The role of blood transfusion (specifically, packed red blood cells-PRBC) is twofold: oxygen transport and volume expansion. Since intravascular volume can be expanded effectively using crystalloids and other colloids, the primary function of PRBC transfusion is the increase in oxygencarrying capacity of the circulation to provide sufficient oxygen to meet the metabolic demands of body tissues. 7 In trauma, hemorrhage results in ischemia and metabolic
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Abstract
The use of blood transfusion in cardiac surgery varies widely. The beneficial effects of blood products are offset by an increase in morbidity and mortality. Despite multiple studies showing an association between blood product exposure and adverse shortand long-term events, it is difficult to determine causality. Nevertheless, the implication is sufficient to warrant the search for alternative strategies to reduce the use of blood products while providing a standard of care that optimizes postoperative outcomes. Aortic surgery, in particular, is associated with an increased risk of bleeding requiring a blood transfusion. There is a paucity of evidence within aortic surgery regarding the deleterious effects of blood products. Here, we review the current evidence regarding patient outcomes after blood transfusion in cardiac surgery, with special emphasis on aortic surgery. acidosis due to anaerobic metabolism. Blood transfusion is required to reverse this derangement. Severely anemic patients also exhibit organ dysfunction due to the reduced oxygen-carrying capacity. 8, 9 Therefore, the true benefits of transfusion are limited to these specific indications. Despite its beneficial effects, blood transfusion is not without harm. Adverse effects are well documented and include acute and chronic hemolytic reactions, nonimmune hemolysis, anaphylaxis, transfusion-related acute lung injury, graft versus host disease, circulatory overload, and infectious disease transmission.
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Immunomodulatory effects influence short-and longterm outcomes. Outcomes are affected by duration of storage, as well as leukocyte level in the PRBC units. Blood products stored for longer than 14 days are associated with an increased risk of prolonged intubation, renal failure, sepsis, multiorgan failure, and in-hospital death, together with a reduction in survival during the first 6 months. The mechanism is not completely understood but might be related to the development of a "storage lesion" decreasing the availability of oxygen delivery, impeding microvascular flow, and increasing systemic inflammation. 10 Moreover, white blood cells contribute to transfusion-related immunomodulation. Nonleukoreduced blood activates the host immune system, changing the immune modulatory profile.
There is a decrease in circulating lymphocytes, modification of the T-cell helper/suppressor ratio, and downregulation of the antigen-presenting cell. These changes make patients increasingly vulnerable to external insults.
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Blood Transfusion in Cardiac Surgery
Cardiac surgical procedures are associated with an increased risk of bleeding. 12 The extent of blood utilization varies widely across institutions, ranging from 3 to 92% of patients. 12 The proportion receiving only one unit of PRBC is 22 to 67%, while 5 to 25% of patients received greater than five units, independent of hospital characteristics.
3
Blood products are used to treat coagulopathies and anemia, thereby limiting bleeding and augmenting oxygen-carrying capacity.
2 Multiple intrinsic and extrinsic factors contribute to the need for blood transfusion. These factors are patient-related and procedure-related. Some patient factors include coagulopathy and platelet disorders, while procedure-related factors include hypothermia and qualitative platelet defects secondary to cardiopulmonary bypass (CPB).
2
Many studies have shown an association between transfusion and increases in short-and long-term mortality, resulting in a shift from the liberal use of blood to a more restrictive and goal-directed strategy. The aims are more efficient blood utilization and reduction in the rate of transfusion-related complications, with an expected improvement in outcomes and long-term quality of life. Importantly, the retrospective nature of these observational studies makes it difficult to assess the exact relationship between blood transfusion and adverse events. The association may be influenced by numerous confounders that might not be accounted for during the statistical analysis.
14-17 One potential confounder that may impact outcomes is the severity of clinical presentation. Inherently high-risk patients, such as those with multiple comorbidities, complex clinical presentations, and emergent operations, naturally tend to have lower survival. Nevertheless, even in studies that evaluate nonhighrisk patients, the outcomes are still conflicting. For instance, while Paone et al showed an increased morbidity and mortality after on-pump CABG with as little as one or two units of PRBC, Koster et al did not show an increase in mortality or adverse perioperative outcomes in patients receiving equal amount of blood products.
18,19
Some centers give blood transfusions to patients with stable cardiovascular disease in anticipation of intraoperative hemorrhage. Paone et al 18 described the routine use of one to two units of PRBC, and showed an association with increased mortality after propensity adjustment (OR, 1.86; 95% CI, 1.21-2.87; p ¼ 0.005). Murphy et al 20 analyzed the effect of giving increasing volumes of blood, comparing outcomes with patients who did not receive transfusions. Patients receiving only one unit of PRBC had a 63% increase in ischemic complications and a 46% increase in infectious complications, while those exposed to two units had an increase of 130% and 136%, respectively. Moreover, they demonstrated an 11% and 21% increase in transfusion cost with one and two units, respectively. They showed not only the adverse association with increasing quantities of blood transfusion but also its existence even with low blood product use, highlighting the harmful effect of this practice.
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Age
Age is another factor that influences outcomes, and elderly patients invariably have more comorbidities than their younger counterparts. Cardiac surgery is increasingly performed in older patients. Preoperative anemia is common in this population, with a prevalence of one in eight patients older than 65 years; 21 and this is reflected in their greater use of blood products. 22 In spite of this, studies have not shown a statistically significant association between transfusion and adverse events in these patients. demonstrated an improvement in 30-day mortality in patients undergoing transfusion who experienced an acute myocardial infarction with low hematocrit (< 24%).
Confounders
Many other variables influence outcomes and act as confounders in any observational study. Indeed, the surgery itself is a risk factor due to the systemic inflammatory response precipitated by the procedure and the use of CPB. 12 Thus, the etiologic association of blood transfusion with mortality is difficult to establish in the complex cardiac surgical patient.
Counterevidence
Recent studies have challenged the negative association of transfusion in cardiac surgical patients. Koster 26 showed an increase in long-term mortality with the use of one unit of PRBC (by univariate analysis), they failed to show this relationship with Cox regression and propensity models. They identified preoperative anemia as a significant confounding factor (p ¼ 0.02) but concluded that a single unit transfusion policy is safe.
26
Differences in methodology, the retrospective and observational nature of the studies, and the lack of randomized trials likely underlie the heterogeneity of the results in the literature (►Tables 1 and 2). The ethical considerations and impracticality of a randomized clinical trial with a lifesaving procedure, such as blood transfusion, may jeopardize research in this area (►Table 1).
Blood Transfusion in Aortic Surgery
Within cardiac surgery, aortic surgery is considered an especially high-risk subspecialty, with many surgeries carrying a considerable risk of bleeding. Complex aortic reconstruction, urgent presentations, multiple suture lines, prolonged CPB, and hypothermia account for the higher risk.
6 Unsurprisingly,
there is a greater likelihood of exposure to blood products.
2,13
Nevertheless, most studies have excluded this group of patients from their analysis, and consequently, current transfusion guidelines are based on literature addressing nonaortic procedures. Current practices in aortic surgery are therefore not based on firm evidence. 6 in their evaluation of transfusion practices, found that the patients in the blood conservation group did indeed have less blood transfused, and had lower morbidity than the control group. However, a difference in mortality was not seen. Argalious et al 11 studied the effect of blood transfusion in patients undergoing endovascular aortic repair. Although they found an association with in-hospital morbidity and mortality in the univariate analysis (OR, 2.94; 95% CI, 1.96-4.46; p < 0.001), propensity matching, and multivariate analysis yielded no statistically significant association (OR, 2.7; 95% CI, 0.8-9.0; p ¼ 0.11). To the best of our knowledge, this is the only study in the field of aortic intervention that directly relates transfusion with outcomes. The endovascular nature of the procedure studied, with its presumably lesser proinflammatory stimulus, may account for the disparity in results compared with the majority of the cardiac surgery literature (►Table 2).
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Impact and Management of Perioperative Anemia
Among cardiothoracic surgery patients, some variables have been found to correlate with the likelihood of receiving a transfusion. These include advanced age, low preoperative hemoglobin concentration, preoperative antiplatelet, and antithrombotic medication, complex cardiac procedures, and redo surgeries, emergency surgery, and noncardiac comorbidities. 2, 12 Among these, anemia is an independent risk factor associated with worse outcomes and has been It is a common observation among aortic surgeons that anemia begets bleeding. That is, the blood needs to be "thick" enough to clot property. Many feel that a hematocrit greater than 30% is required for optimal coagulation.
Transfusion Thresholds
Transfusion thresholds provide guidance on when to transfuse the anemic patient. An appropriate threshold should balance the benefits of increased oxygen delivery with the risks of PRBC transfusion. A Cochrane review of clinical trials in noncardiac surgery and critical care 31 found that transfusing at a lower level (Hg 7-8 g/dL) compared with a higher level (Hg 9-10 g/dL) was associated with a 43% reduction in PRBC requirement (relative risk [RR], 0.57; 95% CI, 0.49-0.65). There was no evidence that transfusing at this more restrictive level impacted 30-day mortality, development of cardiac events, stroke, pneumonia, thromboembolism, and infection (RR, 0.97; 95% CI, 0.81-1.16). Notably, cardiac patients with "active" disease were not studied. Thus, it is difficult to extrapolate the results above to cardiac surgical patients. Those with coronary artery disease (especially acute coronary syndromes) require higher Hg levels to maintain adequate oxygen delivery to the myocardial tissue. A fall in Hg increases the risk of ischemia with ensuing negative outcomes. 
Blood Transfusion in Other Specialties
The negative effects of liberal transfusion practices extend well beyond the field of cardiac surgery. However, the evidence in medical and noncardiac surgical areas is also controversial. 
Possible Solutions
Overall, the evidence points preponderantly toward a more conservative transfusion policy in cardiac surgery. The complexity and bleeding potential of aortic surgery warrants a more individualized approach, incorporating an assessment of the potential for operative mortality, and bleeding. In those patients with a high bleeding risk, efforts can be made to permit yet minimize the amount of administered blood transfusion.
• Preoperatively: Investigate and treat anemia, for example, erythropoietin, iron • Intraoperative factors: meticulous surgical hemostasis, shorter CPB circuits, point of care testing for coagulopathy; salvage procedures (e.g., autologous blood transfusion, cell saver), correction of coagulopathy (antifibrinolytics, fresh frozen plasma, platelets, cryoprecipitate, factor VII) • Availability of traditional and recombinant agents (aminocaproic acid, tranexamic acid, factor VII, and topical hemostatic agents) is laudable. Cardiac surgeons worldwide still bemoan the loss of aprotinin, which produced remarkably dry surgical fields
42
• Postoperative: Careful surveillance for bleeding, regular Hg and hematocrit monitoring, treatment of sepsis (and other complications)
In cases where transfusion is required, it is important to consider the nature of blood being transfused. Specifically, leukoreduced blood and blood that has been stored for less than 14 days have a better safety profile with regards to immediate postoperative and long-term complications.
10
Furthermore, the development of a multidisciplinary transfusion team (with surgeons, anesthesiologists, intensivists, perfusionists, nurses, and blood bankers) may help to ensure judicious use of blood products.
2,13
Although each case should be considered on an individual basis, the current guidelines serve as an adjunct for decisionmaking. Medical and asymptomatic noncardiac surgical patients may benefit from a more restrictive approach, with an Hg threshold of less than 6 to 7 g/dL. For cardiac surgical patients and those with acute coronary syndromes, we must recognize that a more liberal approach (Hg threshold 9-10 g/dL) is beneficial to ensure sufficient oxygen delivery.
Conclusion
Blood transfusion is undoubtedly a lifesaving procedure if used appropriately. Nevertheless, it is not without harm, and there is much controversy surrounding the effects of transfusion on surgical outcomes. Despite the paucity of studies investigating this practice specifically in aortic surgery, there is some evidence showing an association between transfusion and adverse outcomes warranting greater vigilance regarding the use of blood products. Since aortic surgery is a particularly high risk, we advocate a thorough evaluation of the patient that balances the consequences of bleeding and anemia with the putative decreased survival associated with blood products. Further research is required to better define the effect of transfusion on short-and long-term outcomes in aortic surgery patients.
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